Theophylline has been a mainstay in the treatment of asthma for over 50 years. Its therapeutic value stems from a combination of antiinflammatory and bronchodilator activities in addition to its ability to increase diaphragmatic contractility.14 Although the pharmacological effects of theophylline have been studied extensively both in the laboratory and in the clinic, the molecular mechanisms responsible for its activity in asthma remain ill defined. In 
Theophylline has been a mainstay in the treatment of asthma for over 50 years. Its therapeutic value stems from a combination of antiinflammatory and bronchodilator activities in addition to its ability to increase diaphragmatic contractility.14 Although the pharmacological effects of theophylline have been studied extensively both in the laboratory and in the clinic, the molecular mechanisms responsible for its activity in asthma remain ill defined. In fact, several cellular activities probably contribute to its action, including cyclic nucleotide phosphodiesterase inhibition,' 5 adenosine receptor antagonism,6 stimulation of catecholamine release,7 and a poorly understood ability to increase the number and activity of suppressor T lymphocytes. 8 Of theophylline's many activities, phosphodiesterase inhibition may be the most important. Hypothetically, at least two therapeutically beneficial effects could result from inhibition of phosphodiesterase activity and the consequent rise in intracellular adenosine 3',5'-monophosphate (cAMP) or guanCyclic AMP osine 3',5'-monophosphate (cGMP) concentrations in key cells concerned in the pathophysiology of asthma (figure). Firstly, both cAMP and cGMP mediate airway smooth muscle relaxation,9 10 so a rise in either of these second messengers in airway smooth muscle should result in bronchodilatation. Secondly, the ability of PDE inhibitors to increase the cAMP content of inflammatory cells leads to an inhibition of cell activation.5 1112 In principle, then, PDE inhibitors should possess antiinflammatory activity.
Although it is useful in the treatment of asthma, the value of theophylline is limited by a narrow therapeutic index umol/l and cGMP with a Km of 1 iimol/l.
An important point is that, whereas certain isozymes possess a degree of selectivity for cAMP or cGMP, all phosphodiesterases are capable of hydrolysing both cyclic nucleotides. Certain isozymes may also, for various reasons, be inactive in intact tissues. Thus, in the absence of additional information, it is impossible to predict which isozyme or isozymes are responsible for cyclic nucleotide hydrolysis in a tissue containing multiple phosphodiesterases simply by determining which isozymes are present in tissue homogenates.
From the standpoint of drug discovery the synthesis of compounds that possess a substantial degree of selectivity for one isozyme by comparison with others has been critical. 2' These compounds are valuable pharmacological probes with which to assess the importance of various phosphodiesterase isozymes in regulating cyclic nucleotide content in intact tissues. More importantly, isozyme selective phosphodiesterase inhibitors may have therapeutic advantages over non-selective compounds (see below) and several isozyme selective phosphodiesterase inhibitors are, or were, being assessed in clinical studies for various disorders. Some examples are shown in table 2. In contrast to the results with human polymorphonuclear leucocytes, most studies in asthmatic subjects have detected only an additive bronchodilator effect when a beta adrenoceptor agonist and theophylline are given together,3638 though a synergistic interaction has been observed on occasion. '9 One possible explanation for the failure to detect a synergistic interaction in vivo is that theophylline produces bronchodilatation by several cellular mechanisms in addition to phosphodiesterase inhibition.
Several endogenously released agents are ponse to phosphodiesterase inhibitors may be greater in the inflamed lungs of patients with asthma than in non-inflamed tissues. Cyclooxygenase inhibitors and beta adrenoceptor antagonists could reduce the therapeutic activity of phosphodiesterase inhibitors, though to our knowledge neither of these possibilities has been tested.
Airway smooth muscle ROLE OF CYCLIC NUCLEOTIDES
The mechanisms by which cyclic nucleotides mediate smooth muscle relaxation has been the subject of several recent reviews.' 10 4749 An in depth discussion of this topic is beyond the scope of this review, but a brief overview of the proposed roles of cAMP and cGMP in regulating airway smooth muscle tone is given; further details can be obtained elsewhere.9 10 47 48 As depicted schematically in the figure, intracellular cyclic nucleotide content is increased by increasing the rate at which cyclic nucleotides are formed or by decreasing the rate at which they are degraded. Activators of adenylate cyclase (such as beta adrenoceptor agonists and prostaglandins E2 and 12) bind to cell surface receptors and, through a guanine nucleotide binding protein, increase the rate at which Mg2+-ATP is converted to cAMP. In contrast to the regulation of adenylate cyclase, agents such as the nitrovasodilators (for example, sodium nitroprusside, nitroglycerin) and endothelium derived relaxant factor (probably nitric oxide) activate soluble guanylate cyclase activity directly without interacting with a cell cyclic nucleotides by phosphorylating and thus changing the activity of key substrates (such as enzymes and ion transport systems) concerned in the regulation of smooth muscle tone. Several relevant substrates are likely to be phosphorylated by cAMP dependent and cGMP dependent protein kinases in airway smooth muscle. 9 10 In brief, the increases in cAMP or cGMP content can produce airway smooth muscle relaxation by two general mechanisms. Firstly and perhaps most importantly, an increase in cyclic nucleotide concentrations leads to a decrease in the cytosolic free Ca2' concentration by reducing the mobilisation of Ca2+ from intracellular stores, inhibiting the influx of extracellular Ca2', stimulating Ca2+ efflux or increasing Ca2+ sequestration into intracellular storage sites. Secondly, activation of the cAMP or cGMP protein phosphorylation cascades may inhibit the activity of contractile proteins directly. Several of these biochemical pathways are likely to be activated simultaneously and act in a coordinated fashion to reduce airway smooth muscle tone.
Bronchodilators that act through second messenger pathways-for example, beta adrenoceptor agonists and phosphodiesterase inhibitors-should relax airway smooth muscle regardless of the mediator or mediators responsible for inducing bronchoconstriction. This should be an advantage in a disease such as asthma in which several mediators may act in concert to elicit bronchoconstriction.
PHOSPHODIESTERASE ISOZYMES IN AIRWAY SMOOTH MUSCLE
Over the last 15 years, and especially the last five, several reports have described phosphodiesterase isozyme profiles in airway smooth muscle from various species (table  3) .5056 A few caveats must be considered in any discussion of the results of these studies. Firstly, kinetic analyses of enzyme activity have generally been carried out with crude or at best partially purified preparations. To our knowledge, there have been no reports of studies in which every phosphodiesterase isozyme present in airway smooth muscle has been purified to homogeneity. Secondly, airway smooth muscle preparations are not homogeneous in terms of cellular content and at least some of the phosphodiesterase activity present in homogenates of airway smooth muscle will come 57 suggesting that the xanthines examined were relaxing canine trachealis by inhibiting the activity of a specific cAMP or cGMP phosphodiesterase. The results of these studies, the first to describe a correlation between inhibition of distinct phosphodiesterase activities and relaxation of airway smooth muscle, cannot be interpreted unequivocally. One problem was the use of alkylxanthines that inhibited cAMP and cGMP phosphodiesterase activities nonselectively. Consequently, the potency order of the compounds for inhibition of the cAMP phosphodiesterase activity50 was identical to that for inhibition of the cGMP phosphodiesterase activity.57 This and the lack of information on the effect of these compounds on cyclic nucleotide content in intact trachealis strips makes it difficult to determine whether the relaxant response of the trachealis to the phosphodiesterase inhibitors was due to inhibition of either the cAMP or the cGMP phosphodiesterase activity, or both. Finally, a role for PDE V in regulating cGMP content in guinea pig airway smooth muscle is suggested by the observation that SK&F 96231, a selective PDE V inhibitor, relaxes guinea pig isolated trachea in a concentration dependent manner. 65 The biochemical response of guinea pig trachealis to isozyme selective phosphodiesterase inhibitors has not been studied in great detail. The PDE III inhibitor SK&F 94120 and the mixed PDE III/IV inhibitor benzafentrine (AH 21-132) increase cAMP content in muscle rich guinea pig tracheal preparations, though detectable increases in cAMP content are observed only with concentrations of these compounds that produce near maximal relaxation. 6 One final caveat concerns the interpretation of the data discussed in this section: no phosphodiesterase inhibitors possess absolute isozyme specificity. When present in high concentrations all isozyme selective inhibitors will inhibit phosphodiesterases other than the ones against which they are targeted. Certain isozyme selective phosphodiesterase inhibitors may also regulate physiological processes by mechanisms that are unrelated to phosphodiesterase inhibition. For example, the ability of rolipram to inhibit agonist induced generation of inositol phosphates in bovine trachealis may be unrelated to phosphodiesterase inhibition and cAMP accumulation.73 Thus conclusions on the role of individual phosphodiesterase isozymes in intact tissues drawn from experiments with isozyme selective phosphodiesterase inhibitors are somewhat tenuous, particularly in the absence of corroborative biochemical data.
Inflammatory cells ROLE OF CYCLIC NUCLEOTIDES
The vast number of published papers leaves little doubt that cAMP acts as an inhibitory messenger in inflammatory cells.5" 12 In addition to inhibiting inflammatory mediator production and release, it is evident that an increase in cellular cAMP inhibits other functions of inflammatory cells, including chemotaxis, cytotoxicity and cell aggregation. Thus increases in cAMP content have a generalised suppressive influence on human inflammatory cells ( figure) .
More than 20 years ago Lichtenstein and coworkers suggested that an increase in cellular cAMP led to an inhibition of antigen induced histamine release from human basophils.74 This speculation was based on the observation that beta adrenoceptor agonists and theophylline were effective inhibitors of antigen induced histamine release from human mixed leucocyte preparations, and was consistent with the observations made by Schild some 30 years earlier that epinephrine is a potent inhibitor of anaphylactic histamine release from lung tissue. 75 Various compounds that either stimulate adenylate cyclase or inhibit cyclic nucleotide phosphodiesterase (see Much less is known about the role of cGMP in the regulation of inflammatory cell function. An increase in cGMP may enhance antigen induced histamine release from human lung mast cells.87 These studies, however, were carried out on lung parenchymal fragments, so the biochemical data are difficult to interpret. Neither sodium nitroprusside nor dibutyryl cGMP inhibited immunological mediator release from human basophils88 or isolated human lung mast cells in our studies (unpublished observations) Although the precise role of cGMP in regulating inflammatory cell function is uncertain, its effect appears to be modest by comparison with the profound inhibitory effect of cAMP.
PHOSPHODIESTERASE ISOZYMES IN INFLAMMATORY CELLS
The profile of phosphodiesterase isozymes in inflammatory cells has been obtained only recently (table 4) . Chromatographic analyses combined with kinetic and pharmacological characterisations show that PDE IV is the major phosphodiesterase isozyme responsible for catabolising cAMP in several human inflammatory cell types, including mast cells, basophils, monocytes, and neutrophils. In contrast, PDE III is the predominant isozyme in platelets and a combination of PDE III and PDE IV is present in mixed lymphocyte preparations.
The next section looks at the identity of the predominant cAMP phosphodiesterase activity in various inflammatory cells. In virtually all the cells studied so far, however, minor activity from one or more phosphodiesterases has been found in addition to the major activity. In the basophil and platelet, for exam-ple, the additional phosphodiesterase is selective for cGMP and is inhibited by zaprinast, 88"8 suggesting that it is PDE V. On the basis of the substrate specificity this isozyme seems unlikely to have a physiological role in the catabolism of cAMP. Thus selectively inhibiting this isozyme is unlikely to lead to a rise in cellular cAMP.
Basophil and mast cell In the human basophil most of the cAMP hydrolysis activity is accounted for by PDE IV (Km = 1 6 jmol/1).88 A small portion (under 20%) of the activity is attributed to PDE III (Km = 0 3 1M), on the basis of the observations that the low Km isozyme was inhibited by cGMP and the selective PDE III inhibitor SK&F 95654. The phosphodiesterase isozyme profile in human mast cell populations is not known. Mouse mast cells derived from mouse bone marrow contain a single cAMP hydrolysing isozyme with kinetic and pharmacological characteristics of PDE IV.32
Neutrophil
The cAMP PDE activity in the human neutrophils is eluted from DEAE anion exchange columns in a single peak, has a Km of 0 7 pmol/l, and is sensitive to inhibition by the selective PDE IV inhibitors rolipram and Ro 20-1724.9o
These findings suggest that the phosphodiesterase isozyme responsible for hydrolysing cAMP in the human neutrophil is predominantly if not exclusively PDE IV. Lymphocyte Systematic evaluation of the PDE isozyme profile in the various subtypes of lymphocytes has not been performed to our knowledge. Thompson Clinical experience with the use of isozyme selective phosphodiesterase inhibitors for the treatment of asthma is limited. To our knowledge, the first such compound to be examined was zaprinast, an inhibitor ofthe cGMP specific phosphodiesterase (PDE V). In an initial placebo controlled, double blind crossover trial oral zaprinast (10 mg) reduced exercise induced bronchoconstriction in adult asthmatic patients significantly,'07 whereas it failed to inhibit bronchoconstriction induced by histamine. The reason that zaprinast was active against exercise induced bronchoconstriction but not histamine induced bronchoconstriction is not obvious. On the basis of the proposed role of cGMP in airway smooth muscle, we might speculate that the efficacy of zaprinast stemmed from bronchodilator activity. This explanation does not appear to be viable, however, in view of the failure of zaprinast to abrogate histamine induced bronchoconstriction. On the other hand, zaprinast might have altered neural reflexes or mediator release, perhaps through a mechanism unrelated to PDE inhibition. But it had no effect on exercise induced bronchoconstriction in a subsequent study with asthmatic children.'08 Thus the positive results obtained in the earlier study were not repeated in a different group of asthmatic patients.
At least a dozen PDE III inhibitors have been evaluated for inotropic or antithrombotic activity in man but bronchodilator activity has been assessed only for one, enoximone.'09 Pulmonary mechanics were studied before and after an intravenous infusion of enoximone (3 mg/kg) in 19 patients with decompensated chronic obstructive pulmonary disease. Enoximone reduced pulmonary resistance and increased dynamic lung compliance in both spontaneously breathing and artificially ventilated patients. Although long term studies have not been conducted in patients with asthma, these preliminary results suggest that enoximone can reverse bronchoconstriction in man.
Preliminary results on the activity of tibenalast,"10 a PDE IV inhibitor, and benzafentrine,"1' a mixed PDE III/IV inhibitor, also have been reported. The results with tibenalast were equivocal. A single oral 150 mg dose of tibenalast caused a slight but non-significant increase in FEV, in 40 asthmatic subjects.
Because of the putative anti-inflammatory activity of PDE IV inhibitors, it would be of interest to assess the effect of tibenalast over a longer time. Inhalation of benzafentrine (2-32 mg) by non-asthmatic subjects reversed methacholine induced bronchoconstriction, as monitored by changes in specific airways conductance, in a dose dependent manner."' A preliminary report indicates that intravenously administered benzafentrine (40 and 80 mg) produced a modest and transient bronchodilatation, whereas the compound was ineffective when administered by the oral route (9_90 mg)."2
SIDE EFFECTS
With the possible exception of the PDE III inhibitors, clinical experience with isozymeselective phosphodiesterase inhibitors is not yet extensive enough to draw conclusions about the side effect profile of the different classes of compounds. The potential for certain side effects can be predicted based on the anticipated activity of different isozyme selective inhibitors on various organs.97 For example, by virtue of their cardiotonic activity, PDE III inhibitors would be expected to produce an increase in myocardial contractility and modest vasodilation.'>30 Whether such effects would be detrimental in subjects with asthma who were otherwise healthy is unknown. Perhaps ofmore concern is the arrhythmogenic potential of these compounds."3 If such activity is the result of PDE III inhibition per se, it could represent a major limitation to the use of these agents to treat asthma.
The most obvious concern regarding the PDE IV inhibitors stems from their apparent antidepressant activity."s"6 The anti-depressant activity of rolipram and, presumably, other compounds of its class appears to be linked to inhibition of PDE IV in the brain."7 Whether PDE IV inhibitors will produce unacceptable central nervous system effects in individuals who do not suffer from affective disorders remains to be answered. Gastrointestinal disturbances, such as pyrosis, nausea, and vomiting, are frequently reported side effects associated with the use of rolipram.11"l6
Rolipram has also been reported to produce a rapid and pronounced fall in plasma osmolality, probably as a result of an antidiuretic effect; this resolves after seven days' treatment. ' 
